Cargando…
COVID-19 vaccines: Update of the vaccines in use and under development
The ongoing COVID-19 pandemic has imposed a series of challenges on the scientific community. One of the biggest was the development of safe and effective vaccines in record time, which could be achieved through a global effort. A topic of great discussion has been the technology surrounding these v...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier España, S.L.U.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9683840/ http://dx.doi.org/10.1016/j.vacune.2022.11.007 |
_version_ | 1784835141427789824 |
---|---|
author | Marta, Rafaela Angotti Nakamura, Gisele Emy Kondo de Matos Aquino, Bruno Bignardi, Paulo R. |
author_facet | Marta, Rafaela Angotti Nakamura, Gisele Emy Kondo de Matos Aquino, Bruno Bignardi, Paulo R. |
author_sort | Marta, Rafaela Angotti |
collection | PubMed |
description | The ongoing COVID-19 pandemic has imposed a series of challenges on the scientific community. One of the biggest was the development of safe and effective vaccines in record time, which could be achieved through a global effort. A topic of great discussion has been the technology surrounding these vaccines: ranging from the well-known inactivated virus vaccines to the latest RNA vaccines. As vaccines became available, another point also came into question: their efficacy and effectiveness against the original Wuhan strain and its variants. Among the numerous variants, 5 of them (Alpha, Beta, Gamma, Delta and, more recently, Omicron) gained greater prominence due to their epidemiological relevance. In this scenario, with numerous variants and several vaccine options, scientific information can often be mismatched. This review aims to provide an overview of the efficacy, effectiveness, and safety of 11 vaccines in use or under development against the original Wuhan strain and the variants of concern identified by the World Health Organisation (WHO). Simultaneously, we aim to explore possible scenarios that can be expected shortly regarding new variants and vaccines. Overall, COVID-19 vaccines have satisfactory efficacy and loss of effectiveness against SARS-CoV-2 variants, especially the Omicron strain. |
format | Online Article Text |
id | pubmed-9683840 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Published by Elsevier España, S.L.U. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96838402022-11-25 COVID-19 vaccines: Update of the vaccines in use and under development Marta, Rafaela Angotti Nakamura, Gisele Emy Kondo de Matos Aquino, Bruno Bignardi, Paulo R. Vacunas (English Edition) Review Article The ongoing COVID-19 pandemic has imposed a series of challenges on the scientific community. One of the biggest was the development of safe and effective vaccines in record time, which could be achieved through a global effort. A topic of great discussion has been the technology surrounding these vaccines: ranging from the well-known inactivated virus vaccines to the latest RNA vaccines. As vaccines became available, another point also came into question: their efficacy and effectiveness against the original Wuhan strain and its variants. Among the numerous variants, 5 of them (Alpha, Beta, Gamma, Delta and, more recently, Omicron) gained greater prominence due to their epidemiological relevance. In this scenario, with numerous variants and several vaccine options, scientific information can often be mismatched. This review aims to provide an overview of the efficacy, effectiveness, and safety of 11 vaccines in use or under development against the original Wuhan strain and the variants of concern identified by the World Health Organisation (WHO). Simultaneously, we aim to explore possible scenarios that can be expected shortly regarding new variants and vaccines. Overall, COVID-19 vaccines have satisfactory efficacy and loss of effectiveness against SARS-CoV-2 variants, especially the Omicron strain. Published by Elsevier España, S.L.U. 2022 2022-11-24 /pmc/articles/PMC9683840/ http://dx.doi.org/10.1016/j.vacune.2022.11.007 Text en © 2022 Published by Elsevier España, S.L.U. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Review Article Marta, Rafaela Angotti Nakamura, Gisele Emy Kondo de Matos Aquino, Bruno Bignardi, Paulo R. COVID-19 vaccines: Update of the vaccines in use and under development |
title | COVID-19 vaccines: Update of the vaccines in use and under development |
title_full | COVID-19 vaccines: Update of the vaccines in use and under development |
title_fullStr | COVID-19 vaccines: Update of the vaccines in use and under development |
title_full_unstemmed | COVID-19 vaccines: Update of the vaccines in use and under development |
title_short | COVID-19 vaccines: Update of the vaccines in use and under development |
title_sort | covid-19 vaccines: update of the vaccines in use and under development |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9683840/ http://dx.doi.org/10.1016/j.vacune.2022.11.007 |
work_keys_str_mv | AT martarafaelaangotti covid19vaccinesupdateofthevaccinesinuseandunderdevelopment AT nakamuragiseleemykondo covid19vaccinesupdateofthevaccinesinuseandunderdevelopment AT dematosaquinobruno covid19vaccinesupdateofthevaccinesinuseandunderdevelopment AT bignardipaulor covid19vaccinesupdateofthevaccinesinuseandunderdevelopment |